Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Banz

Showing results (11-20 of 12) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 12 results.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainKurt Banz, Helge Bischoff, Matthias Brunner, et al.
Pharmacoeconomics|April 4, 2002
Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusionStephan H Duda, Gunnar Tepe, Mohan Bala, et al.
Pageof 2

Showing results (11-20 of 12) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 12 results.
Lung Cancer (Amsterdam, Netherlands)|May 20, 2011
Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and SpainKurt Banz, Helge Bischoff, Matthias Brunner, et al.
Pharmacoeconomics|April 4, 2002
Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusionStephan H Duda, Gunnar Tepe, Mohan Bala, et al.
Pageof 2